A Phase I/Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Chinese Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors With Expansion to Selected Indication(s)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck KGaA
- 20 Aug 2019 Planned End Date changed from 2 Aug 2019 to 2 Mar 2020.
- 20 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2019 Planned End Date changed from 21 Oct 2019 to 2 Aug 2019.